Copyright
©The Author(s) 2015.
World J Gastroenterol. May 21, 2015; 21(19): 5985-5994
Published online May 21, 2015. doi: 10.3748/wjg.v21.i19.5985
Published online May 21, 2015. doi: 10.3748/wjg.v21.i19.5985
Table 1 Baseline characteristics of the study group
| Bio-three (n = 23) | Placebo (n = 23) | |
| Male/female | 16/7 | 12/11 |
| Age (yr, mean ± SD) | 44.8 ± 13.8 | 42.9 ± 15.9 |
| Age of onset (yr) | 37.1 ± 14.4 | 36.0 ± 14.2 |
| Disease duration (yr, mean ± SD) | 8.0 ± 6.3 | 6.7 ± 5.9 |
| Left colon | 6 | 9 |
| Proctosigmoiditis | 6 | 5 |
| Total/subtotal | 11 | 9 |
| Concomitant drug | ||
| Pentasa | 11 | 13 |
| Salazopyrin | 10 | 9 |
| Pentasa + salazopyrin | 1 | 0 |
| Nothing | 1 | 1 |
- Citation: Yoshimatsu Y, Yamada A, Furukawa R, Sono K, Osamura A, Nakamura K, Aoki H, Tsuda Y, Hosoe N, Takada N, Suzuki Y. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World J Gastroenterol 2015; 21(19): 5985-5994
- URL: https://www.wjgnet.com/1007-9327/full/v21/i19/5985.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i19.5985